Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: The significance of baseline glomerular filtration rate

被引:45
作者
Arora, Satish [1 ,7 ]
Gude, Einar
Sigurdardottir, Vilborg [2 ]
Mortensen, Svend Aage [3 ]
Eiskjaer, Hans [3 ]
Riise, Gerdt [2 ]
Mared, Lena [4 ]
Bjortuft, Oystein
Ekmehag, Bjorn [4 ]
Jansson, Kjell [5 ]
Simonsen, Svein
Aukrust, Pal [7 ]
Solbu, Dag [6 ]
Iversen, Martin [3 ]
Gullestad, Lars [7 ]
机构
[1] Oslo Univ Hosp, Dept Cardiol, Rikshosp, N-0027 Oslo, Norway
[2] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden
[3] Skeiby Univ Hosp, Aarhus, Denmark
[4] Lund Hosp, Lund, Sweden
[5] Linkoping Univ Hosp, Ctr Heart, Linkoping, Sweden
[6] Novartis Norge, Oslo, Norway
[7] Univ Oslo, Oslo, Norway
关键词
thoracic transplantation; heart and lung transplantation; everolimus; CNI reduction; renal failure; GFR improvement; SOLID-ORGAN TRANSPLANTATION; CHRONIC KIDNEY-DISEASE; HEART-TRANSPLANTATION; SIROLIMUS; NEPHROTOXICITY; CYCLOSPORINE; PROTEINURIA; CONVERSION; MECHANISM; CERTICAN;
D O I
10.1016/j.healun.2011.12.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The NOCTET (NOrdic Certican Trial in HEart and lung Transplantation) trial demonstrated that everolimus improves renal function in maintenance thoracic transplant (FIX) recipients. Nevertheless, introduction of everolimus is not recommended for patients with advanced renal failure. We evaluated NOCTET data to assess everolimus introduction amongst TTx recipients with advanced renal failure. METHODS: This 12-month multicenter Scandinavian study randomized 282 maintenance TTx recipients to everolimus introduction with calcineurin inhibitor (CNI) reduction or standard CNI therapy. The measured glomerular filtration rate (mGFR) was noted at baseline and after 1-year using Cr-ethylenediarninetetraacetic acid clearance. RESULTS: In 21 patients with a baseline mGFR of 20 to 29 ml/min/1.73 m(2), renal function improved in the everolimus group compared with the control group ((Delta mGFR 6.7 +/- 9.0 vs -1.6 +/- 5.1 ml/min/1.73 m(2); p = 0.03). Amongst 173 patients with moderate renal impairment (mGFR 30-59 ml/min/1.73 m(2)), renal function improvement was also greater amongst everolimus patients than in controls (Delta mGFR 5.1 +/- 11.1 vs -0.5 +/- 8.7 ml/min/1.73 m(2); p < 0.01). In 55 patients with mGFR 60 to 89 ml/min/1.73 m(2), mGFR did not change significantly in either group. Improvement in mGFR was limited to patients with a median time since TTx of less than 4.6 years and was also influenced by CM reduction during the study period. CONCLUSIONS: Everolimus introduction and reduced CNI significantly improved renal function amongst maintenance TTx patients with pre-existing advanced renal failure. This beneficial effect was limited to patients undergoing conversion in less than 5 years after TTx, indicating a window of opportunity that is appropriate for pharmacologic intervention with everolimus. J Heart Lung Transplant 2012;31:259-65 (C) 2012 International Society for Heart and Lung Transplantation. All rights reserved.
引用
收藏
页码:259 / 265
页数:7
相关论文
共 20 条
  • [1] Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling
    Abraham, RT
    [J]. CURRENT OPINION IN IMMUNOLOGY, 1998, 10 (03) : 330 - 336
  • [2] Prognostic importance of renal function 1 year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy
    Arora, Satish
    Andreassen, Arne
    Simonsen, Svein
    Gude, Einar
    Dahl, Christen
    Skaardal, Rita
    Hoel, Ina
    Geiran, Odd
    Gullestad, Lars
    [J]. TRANSPLANTATION, 2007, 84 (02) : 149 - 154
  • [3] Chronic kidney disease after nonrenal solid-organ transplantation
    Bloom, Roy D.
    Reese, Peter P.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (12): : 3031 - 3041
  • [4] Campistol JM, 2000, TRANSPLANTATION, V69, pSS5
  • [5] Renal protective strategies in heart transplant patients
    Cantarovich, Marcelo
    [J]. CURRENT OPINION IN CARDIOLOGY, 2007, 22 (02) : 133 - 138
  • [6] Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity
    Flechner, Stuart M.
    Kobashigawa, Jon
    Klintmalm, Goran
    [J]. CLINICAL TRANSPLANTATION, 2008, 22 (01) : 1 - 15
  • [7] Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation
    Gude, Einar
    Gullestad, Lars
    Arora, Satish
    Simonsen, Svein
    Hoel, Ina
    Hartmann, Anders
    Holdaas, Hallvard
    Fiane, Arnt E.
    Geiran, Odd R.
    Andreassen, Arne K.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2010, 29 (06) : 641 - 647
  • [8] Everolimus With Reduced Calcineurin Inhibitor in Thoracic Transplant Recipients With Renal Dysfunction: A Multicenter, Randomized Trial
    Gullestad, Lars
    Iversen, Martin
    Mortensen, Svend-Aage
    Eiskjaer, Hans
    Riise, Gerdt C.
    Mared, Lena
    Bjortuft, Oystein
    Ekmehag, Bjorn
    Jansson, Kjell
    Simonsen, Svein
    Gude, Einar
    Rundqvist, Bengt
    Fagertun, Hans E.
    Solbu, Dag
    Bergh, Claes-Hakan
    [J]. TRANSPLANTATION, 2010, 89 (07) : 864 - 872
  • [9] Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients
    Lehmkuhl, Hans B.
    Mai, Daniel
    Dandel, Michael
    Knosalla, Christoph
    Hiemann, Nicola E.
    Grauhan, Onnen
    Huebler, Michael
    Pasic, Miralem
    Weng, Yuguo
    Meyer, Rudolph
    Rothenburger, Markus
    Hummel, Manfred
    Hetzer, Roland
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (07) : 700 - 704
  • [10] National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
    Levey, AS
    Coresh, J
    Balk, E
    Kausz, AT
    Levin, A
    Steffes, MW
    Hogg, RJ
    Perrone, RD
    Lau, J
    Eknoyan, G
    [J]. ANNALS OF INTERNAL MEDICINE, 2003, 139 (02) : 137 - 147